Table 1

Characteristics of included studies

Implemented models
n=50 (%)*
Non-implemented models
n=17 (%)
All reports
N=67 (%)
Country which the model applies to
 Australia31 (62)14 (82)45 (67)
 USA9 (18)2 (12)11 (16)
 Canada6 (12)1 (6)7 (10)
 New Zealand2 (4)0 (0)2 (3)
 Greenland1 (2)0 (0)1 (2)
 Taiwan1 (2)0 (0)1 (2)
Year of publication
 Pre-19802 (4)0 (0)2 (3)
 1980–19891 (2)0 (0)1 (2)
 1990–19994 (8)2 (12)6 (9)
 2000–200912 (24)1 (6)13 (19)
 2010–202031 (62)14 (82)45 (67)
Eye disease targeted
 Diabetic retinopathy26 (52)4 (24)30 (45)
 All eye care8 (16)8 (47)16 (24)
 Trachoma9 (18)2 (12)11 (16)
 Cataract3 (6)1 (5)4 (6)
 Refractive error2 (4)2 (12)4 (6)
 Glaucoma1 (2)0 (0)1 (1.5)
 Low vision1 (2)0 (0)1 (1.5)
Main clinical service in the model
 Screening26 (52)3 (18)29 (43)
 Non-specific/general6 (12)8 (47)14 (21)
 Surgery (excluding trichiasis surgery)4 (2)1 (6)5 (7)
 Optometry2 (4)2 (12)4 (6)
 Health promotion/training2 (4)1 (6)3 (4)
 Rehabilitation1 (2)0 (0)1 (1.5)
 SAFE for trachoma†
  ►Surgery4 (2)2 (12)6 (9)
  ►Antibiotics4 (2)2 (12)6 (9)
  ►Facial cleanliness6 (12)2 (12)8 (12)
  ►Environmental change3 (6)2 (12)5 (7)
  • *Percentage of the total number of studies for each of the three groups.

  • †Some trachoma reports describe more than one SAFE component.